KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

This study tests a personalized cancer vaccine targeting KRAS gene mutations, combined with two immunotherapy drugs (balstilimab and botensilimab), in patients with advanced colorectal cancer or pancreatic cancer whose tumors do not respond to immunotherapy alone (MSS/MMR-proficient tumors). KRAS mutations are very common in these cancers and have historically been difficult to target. **You may be eligible if...** - You are 18 or older with confirmed pancreatic cancer or colorectal cancer - Your tumor has a specific KRAS gene mutation included in the vaccine - Your tumor has measurable disease and is accessible for biopsies - You have completed 4–6 months of standard first-line chemotherapy for your cancer type **You may NOT be eligible if...** - Your tumor does not have one of the targeted KRAS mutations - You are unable or unwilling to undergo tumor biopsies - You have insufficient tissue for genetic testing Talk to your doctor to see if this trial is right for you.